Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes or Acute Myeloid Leukemia

About the trial

Sponsor

Fred Hutchinson Cancer Center (with Medexus Pharma, Inc.)

Tested

Clofarabine (drug), Fludarabine (drug), Hematopoietic Cell Transplantation (procedure), Total-Body Irradiation (radiation), Treosulfan (drug), Echocardiography Test (procedure), Multigated Acquisition Scan (procedure), Lumbar Puncture (procedure), Bone Marrow Aspiration (procedure), Bone Marrow Biopsy (procedure), Biospecimen Collection (procedure)

Dates

Started 2023-08-11; completion 2026-07-16

Results posted

Not yet

This phase II trials studies the effect of treosulfan-based versus clofarabine-based conditioning regimens before donor hematopoietic stem cell transplant in treating patients with myelodysplastic syndromes or acute myeloid leukemia. Chemotherapy drugs, such as treosulfan, fludarabine, and clofarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy and total-body irradiation before a donor hematopoietic stem cell transplant helps kill cancer cells in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow. When …

From ClinicalTrials.gov, last updated 2026-08-06. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Medexus Pharma, Inc. reported $138,552 in research payments for this study in 2025 (2 payments).

Products named: Grafapex

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.